An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

New England Journal of Medicine
November 12, 2020 Vol. 383 No. 20


Original Article
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Lisa A. Jackson, M.D., M.P.H., et al.
We conducted a first-in-human phase 1 clinical trial in healthy adults to evaluate the safety and immunogenicity of mRNA-1273. Here we report interim results of the trial.
The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 number, NCT04283461. opens in new tab).
This article was published on July 14, 2020, and updated on August 25, 2020, at